Nutra Pharma Sponsors Educational Website for Adrenomyelonueropathy (AMN)
RedNova Tue, 16 Jan 2007 10:07 AM PST
Nutra Pharma Corp. (OTCBB:NPHC), a biotechnology company that is developing drugs for HIV and Multiple Sclerosis has today announced that it has sponsored AMNhelp.com, a website dedicated to educating patients and providing information about Adrenomyeloneuropathy (AMN).
Doctors knew I had MS for 11 years before they told me
Daily Mail Tue, 16 Jan 2007 2:43 AM PST
A father's 11-year nightmare struggle to be diagnosed with MS has exposed the scandal of how consultants withhold bad news
UPDATE 2-Merck Serono finishes enrolment for MS pill trial
Reuters - USA
Analysts at Dresdner Kleinwort said it now seemed possible cladribine might beat Novartis' FTY720 to market as the first oral multiple sclerosis therapy, ...
Analysis: Forest impresses Street
Science Daily (press release) - USA
Analysis: Biogen Idec posts strong Q3 (November 1, 2006) -- Biogen Idec posted robust third-quarter results, driven by strong performances from Tysabri and ...
Options expand for Crohn's disease patients
Naples Daily News Mon, 15 Jan 2007 9:22 PM PST
After decades of relying on little more than steroids, victims of a painful digestive disease are starting to see a wider range of treatment options, from new drugs to promising surgical techniques. Crohn's disease, a debilitating and incurable digestive ailment, affects about 1 million people worldwide — a 10-fold increase since World War II by some estimates, which doctors speculate is due to a ...
Conversation with…Dr. Jeffrey Hyams Top pediatric GI sees research ...
Connecticut Jewish Ledger - West Hartford,CT,USA
... the primary investigator for the two largest pediatric clinical trials of new medications involving Remicade (infliximab) and Tysabri (natalizumab). ...
FDA runs protection racket for Big Pharma
By Evelyn Pringle
Online Journal Contributing Writer
http://onlinejourna l.com/artman/ publish/article_ 1626.shtml
Jan 11, 2007
Why would Americans trust the FDA to regulate the
pharmaceutical industry? Since the Bush administration
took office the FDA has become the industry's partner
in crime.
The most notorious protection scheme put in place by
the FDA and Big Pharma is the preemption policy that
bans private lawsuits against drug companies in state
courts once a drug and its label have been approved by
the FDA.
On January 18, 2006, the FDA issued new rules for the
labeling of prescription drugs, and in the preamble to
the rules on page 43, the FDA says, State law actions
“threaten FDA’s statutorily prescribed role as the expert Federal agency responsible for
evaluating and regulating drugs,” requiring lay
persons to second-guess its expert assessments of a
drug’s risks and benefits.
So, after all of the concerns raised about the FDA's
failure to protect consumers against dangerous
products over the last several years, by top experts
from all over the world, the FDA has hereby declared
itself the sole authority on decisions regarding
prescription drugs, including whether a drug's label
contains adequate descriptions of indications for use,
risks and benefits...
Merck Serono/BioMarin's PKU drug shows promise
Pharma Times (subscription) - London,UK
Analysts believe cladribine might now beat Novartis' FTY720 (fingolimod) to market as the first oral MS therapy, with an expected launch in 2010 or 2011. ...
RedNova Tue, 16 Jan 2007 10:07 AM PST
Nutra Pharma Corp. (OTCBB:NPHC), a biotechnology company that is developing drugs for HIV and Multiple Sclerosis has today announced that it has sponsored AMNhelp.com, a website dedicated to educating patients and providing information about Adrenomyeloneuropathy (AMN).
| Merck Serono Completes Enrollment of MS Trial RedNova Tue, 16 Jan 2007 7:08 AM PST Merck Serono has said that patient enrollment has been completed in the phase III trial evaluating the efficacy and safety of its oral formulation of cladribine for the treatment of multiple sclerosis. |
| Join Maggie Rodriguez & Rene Ruiz At MS Gala CBS 4 Miami Mon, 15 Jan 2007 4:18 PM PST What's hot for spring in the world of fashion? One of South Florida's hottest designers, Rene Ruiz, will debut his new spring collection at the 24th annual Multiple Sclerosis Luncheon and Fashion Show on Wednesday but CBS4 News Anchor Maggie Rodriguez got an exclusive preview Monday. |
| Merck Serono Completes Patient Enrollment in CLARITY Phase III Pivotal Clinical Trial of Oral Cladribine RedNova Tue, 16 Jan 2007 1:09 AM PST GENEVA, Switzerland, January 16 /PRNewswire-Fi |
| Sativex phase III neuropathic pain trials show benefits: GW Pharma PharmaBiz Mon, 15 Jan 2007 10:48 PM PST GW Pharmaceuticals plc announces preliminary results of two phase III studies of Sativex, its cannabinoid spray medicine, in peripheral neuropathic pain. |
Doctors knew I had MS for 11 years before they told me
Daily Mail Tue, 16 Jan 2007 2:43 AM PST
A father's 11-year nightmare struggle to be diagnosed with MS has exposed the scandal of how consultants withhold bad news
UPDATE 2-Merck Serono finishes enrolment for MS pill trial
Reuters - USA
Analysts at Dresdner Kleinwort said it now seemed possible cladribine might beat Novartis' FTY720 to market as the first oral multiple sclerosis therapy, ...
Analysis: Forest impresses Street
Science Daily (press release) - USA
Analysis: Biogen Idec posts strong Q3 (November 1, 2006) -- Biogen Idec posted robust third-quarter results, driven by strong performances from Tysabri and ...
Options expand for Crohn's disease patients
Naples Daily News Mon, 15 Jan 2007 9:22 PM PST
After decades of relying on little more than steroids, victims of a painful digestive disease are starting to see a wider range of treatment options, from new drugs to promising surgical techniques. Crohn's disease, a debilitating and incurable digestive ailment, affects about 1 million people worldwide — a 10-fold increase since World War II by some estimates, which doctors speculate is due to a ...
Conversation with…Dr. Jeffrey Hyams Top pediatric GI sees research ...
Connecticut Jewish Ledger - West Hartford,CT,USA
... the primary investigator for the two largest pediatric clinical trials of new medications involving Remicade (infliximab) and Tysabri (natalizumab). ...
FDA runs protection racket for Big Pharma
By Evelyn Pringle
Online Journal Contributing Writer
http://onlinejourna l.com/artman/ publish/article_ 1626.shtml
Jan 11, 2007
Why would Americans trust the FDA to regulate the
pharmaceutical industry? Since the Bush administration
took office the FDA has become the industry's partner
in crime.
The most notorious protection scheme put in place by
the FDA and Big Pharma is the preemption policy that
bans private lawsuits against drug companies in state
courts once a drug and its label have been approved by
the FDA.
On January 18, 2006, the FDA issued new rules for the
labeling of prescription drugs, and in the preamble to
the rules on page 43, the FDA says, State law actions
“threaten FDA’s statutorily prescribed role as the expert Federal agency responsible for
evaluating and regulating drugs,” requiring lay
persons to second-guess its expert assessments of a
drug’s risks and benefits.
So, after all of the concerns raised about the FDA's
failure to protect consumers against dangerous
products over the last several years, by top experts
from all over the world, the FDA has hereby declared
itself the sole authority on decisions regarding
prescription drugs, including whether a drug's label
contains adequate descriptions of indications for use,
risks and benefits...
Merck Serono/BioMarin's PKU drug shows promise
Pharma Times (subscription) - London,UK
Analysts believe cladribine might now beat Novartis' FTY720 (fingolimod) to market as the first oral MS therapy, with an expected launch in 2010 or 2011. ...
posted by Bill at 10:10 PM
0 Comments:
Post a Comment
<< Home